Israel's Elbit Systems sees further growth from Iran war

Order backlog rose to $28.1 billion at end-2025 from $22.6 billion in 2024 (72% external; >50% of backlog slated for 2026-27), underpinning management's growth outlook for 2026. Revenue was up 16% to $7.9 billion and adjusted EPS rose to $12.75 (from $8.76), with Q4 adjusted EPS $3.56 (vs $2.66) and quarterly revenue topping $2.0 billion for the first time; the company will pay a $1.00 quarterly dividend. Management cites a surge in international demand tied to the US‑Israel war with Iran and battle-tested systems (including an in-development airborne high-power laser order), and shares jumped 4.1%, accumulating a 51% gain YTD.

Analysis

Battlefield validation is a force multiplier for niche defense vendors: systems used in live operations compress buyer due-diligence and move procurement from “study” to “urgent buy,” shifting value capture from one‑time hardware sales to higher‑margin sustainment, training and software upgrades. Expect a material lift in aftermarket gross margins as deployed fleets require spares, sensor replacements and software patches — these revenue streams scale faster and recur longer than initial platform sales, improving long‑term FCF visibility if supply can keep pace.

The chief operational constraint is not demand but constrained upstream supply of specialty components (precision explosives, laser diodes, RF mmWave chips, high‑reliability power electronics) and qualified assembly capacity. Those bottlenecks create an arbitrage: companies that can vertically integrate or secure long‑term component contracts will preserve margins, while others face margin erosion or delayed deliveries. Time horizons bifurcate—near term (weeks–quarters) for order announcements and tactical margin swings, medium term (6–18 months) for production scaling and recognition, and multi‑year for sustainment and product upgrades revenue to fully materialize.

Macro and political tail risks are asymmetric: rapid de‑escalation or diplomatic accommodation would remove the catalyst quickly, while export controls, end‑use restrictions or tech proliferation concerns could constrain addressable markets and invite higher certification costs. Market prices likely already embed a premium for “battle proven” status; the stock’s path will be driven by cadence of export contract awards, public FMS approvals, and demonstrable improvements in supply‑chain resilience rather than headline operational tempo alone.

Key Decisions for Investors

• Long ESLT (equity) — buy a 6–12 month position sized for 3–5% portfolio exposure. Target +30–40% upside on conversion of export backlog and aftermarket margins; tactical stop at -18% to limit drawdown if diplomatic de‑escalation occurs.
• Options play — buy 12‑18 month ESLT LEAP calls (or a 12‑month call debit spread to cap cost). Max premium loss limited; aim for 2.5–4x payoff if multiple large export wins are announced and production scales in 9–15 months.
• Relative trade: long ESLT / short LMT (equal notional) — 6–12 month horizon. Rationale: capture faster export agility and aftermarket growth in ESLT versus US primes’ FMS timing; target 15–25% relative outperformance, hedge broad defense cyclicality.
• Downside hedge — buy 3–6 month ESLT puts or put spreads sized to cover 30–50% of the long position. This protects against sudden de‑escalation, export curbs, or contract delivery failures that could cause rapid re‑rating.